Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Guide reveals that non-smokers require different treatment for lung cancer

A committee of scientists led by Johns Hopkins investigators has published a new guide to the biology, diagnosis and treatment of lung cancer in never-smokers, fortifying measures for what physicians have long known is a very different disease than in smokers.

17 Sep 2009

Weis Markets to hold low-cost flu shot program

Beginning this month, Weis Markets will hold more than 100 low-cost flu shot clinics in its Maryland, New Jersey, Pennsylvania and West Virginia stores. In addition, as part of its WEISCARE Adult Immunization program, many Weis Markets' pharmacies will offer flu shots as an on-going service.

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Fully-insured members of Capital BlueCross to receive coverage for administration fee for H1N1 Flu vaccine

Capital BlueCross announced today that it will cover an administration fee for the H1N1 Flu vaccine for fully-insured members and those with individual coverage during the upcoming 2009-2010 flu season. Self-funded groups may opt to have their coverage customized to include this benefit.

17 Sep 2009

FDA approves H1N1 vaccine, paves way for large-scale U.S. vaccination campaign

HHS Secretary Kathleen Sebelius announced Tuesday during a House Energy and Commerce Committee hearing that H1N1 (swine flu) vaccines produced by four manufacturers — CSL Ltd., Novartis, Sanofi-Pasteur and Medimmune — had won FDA approval, paving the way for a U.S. large-scale vaccination campaign, The Wall Street Journal reports. The application for GlaxoSmithKline PLC's vaccine is still being considered (Dooren/Favole, 9/15).

17 Sep 2009

HIRC investigates the impact of infrastructure on pathogens and micro-organisms

The spread of swine flu and other infectious diseases could be dramatically reduced by revolutionising the way that the places we live in are designed and built.

17 Sep 2009

Administrative cost of H1N1 vaccine to be covered for CIGNA's customers

The spread of the H1N1 influenza virus has the potential to make this year’s flu season more severe than usual. The Centers for Disease Control and Prevention (CDC) has designated vaccination as the most powerful public health tool to control influenza.

17 Sep 2009

H1N1 influenza prevention campaign launched

Children's Hospital of Wisconsin today announced the launch of an H1N1 influenza prevention campaign geared toward informing educators, parents, caregivers and children of all ages on the importance of practicing healthy habits this cold and flu season.

17 Sep 2009

i365’s EVault Plug-n-Protect chosen to back up critical patient and business data of Medical Business Service

i365, Inc., A Seagate Company (NASDAQ: STX), today announced that Medical Business Service, Inc. has moved to i365’s EVault Plug-n-Protect appliance for its complete data protection and recovery capabilities. Headquartered in Coral Gables, Florida, and the largest privately owned patient billing services company for hospital-based physicians, MBS required a reliable, efficient data protection solution that would allow it to back up critical patient and business data across the company’s thirteen branches.

16 Sep 2009

Inovio’s novel platform for developing DNA based vaccines to be discussed at EmTech

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim, CEO, has been invited to present at EmTech, the Emerging Technologies Conference hosted by MIT and produced by MIT’s Technology Review magazine. The conference will take place September 22nd - 24th on the MIT campus in Cambridge, MA.

16 Sep 2009

CEL-SCI to commence its LEAPS-H1N1 clinical trial following FDA approval

CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today that the U.S. Food and Drug Administration (FDA) has indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients.

16 Sep 2009

Winner of LA's Best Award 2009

Los Angeles dentist, Dr. Sam Muslin, DDS, MAGD, has been awarded LA's Best Award (tm) 2009 for his leading edge, high quality dentistry.

16 Sep 2009

Understanding Mexico's management of the A(H1N1) outbreak

When the hitherto undetected A(H1N1) influenza attacked Mexico explosively in late April 2009, the world watched with critical attention as that country's leaders scrambled to manage the emerging public health crisis.

16 Sep 2009

Free caregivers provided to veterans and their spouses by TheraCare

Now, free long term care services, both home and community based, are being offered to qualified veterans and their spouses by TheraCare Home Health and Staffing, LLC.

16 Sep 2009

MDVIP's medical director suggests preventive measures for flu

Dr. Bernard Kaminetsky, the medical director of MDVIP, a national network of affiliated primary care doctors focused on preventive care, recommends, “Talk to your primary care physician now about the flu, both seasonal and H1N1 flu. Your primary care doctor is the one who can best prepare you for the upcoming season with vaccinations as well as information specific to you.”

16 Sep 2009

Pros and cons of HIV treatments in developing countries

Palumbo is co-leading a clinical study of anti-HIV medicines in Africa and India for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT). The randomized trial found that a cohort of 82 HIV-infected children ages 6 to 35 months responded better to treatment with the protease-inhibiting drug lopinavir (LPV/r) than did a cohort of 82 children in the same age group who received the anti-retroviral drug nevirapine (NVP).

16 Sep 2009

FDA approves sBLA for Influenza A (H1N1) 2009 Monovalent Vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.

16 Sep 2009

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics, Inc. (CTI) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

16 Sep 2009

BioMedReports.Com issues special investigative report on CEL-SCI

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special investigative report on CEL-SCI Corporation.

16 Sep 2009

Clinical trial data of Lipsovir presented at ICAAC

Medivir presented Lipsovir (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting.

16 Sep 2009